R. D. Gascoyne, L. Lamant, J. I. Martin-Subero, V. S. Lestou, N. L. Harris, H. K. Müller-Hermelink, J. F. Seymour, L. J. Campbell, D. E. Horsman, I. Auvigne, E. Espinos, R. Siebert and G. Delsol, “ALK-Positive Diffuse Large B-Cell Lymphoma Is Associated with ClathrinALK Rearrangements: Report of 6 Cases,” Blood, Vol. 102, No. 7, 2003, pp. 2568-2573. doi:10.1182/blood-2003-03-0786

has been cited by the following article:

• TITLE: Collision Anaplastic Large Cell Lymphoma (T-Cell/Histiocyte-Rich) and Diffuse Large B Cell Lymphoma: A Pathologic and Clinical Evaluation

  AUTHORS: Lakshmi Rajappannair, Elaine Lam, Don Benson, Frederick Racke, Steven Devine, Weiqiang Zhao

  KEYWORDS: Collision Lymphoma; ALCL; DLBCL

  JOURNAL NAME: Journal of Cancer Therapy, Vol.3 No.6, December 14, 2012

  ABSTRACT: A collision tumor of T and B-cell lymphomas occur rarely. In this article we report a collision tumor of anaplastic large cell lymphoma and diffuse large B cell lymphoma in a 46 year old female. The tumor showed predominantly neoplastic anaplastic large cell lymphoma (ALCL) component expressing CD30 and ALK with smaller areas of CD20+ diffuse large B cell lymphoma component. Polymerase chain reaction for T-cell receptor beta and IgH (VDJ) gene rearrangements detected a clonal T cell and a clonal B cell population. The patient developed CSF involvement approximately 3 months after treatment. CSF analysis at this time showed only monoclonal T cells, probably due to clearing of the B cell component by the chemotherapy. To the best of our knowledge this is the first case report of a composite tumor of ALCL (lymphohistiocytic variant) and DLBCL. This case raises issues related to the classification of these composite lymphomas and the treatment on initial presentation and during relapse.